CTI BIOPHARMA CORP - FORM 10-K - EX-23.2 - CONSENT OF MARCUM LLP - February 16, 2011

Attached files

file filename
10-K - FORM 10-K - CTI BIOPHARMA CORPd10k.htm
EX-32 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER - CTI BIOPHARMA CORPdex32.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 - CTI BIOPHARMA CORPdex311.htm
EX-23.1 - CONSENT OF STONEFIELD JOSEPHSON, INC. - CTI BIOPHARMA CORPdex231.htm
EX-12.1 - STATEMENT RE: COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES - CTI BIOPHARMA CORPdex121.htm
EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - CTI BIOPHARMA CORPdex211.htm
EX-10.24 - FORM OF AMENDMENT TO AMENDMENT TO EQUITY/LONG-TERM INCENTIVE AWARD AGREEMENT - CTI BIOPHARMA CORPdex1024.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 - CTI BIOPHARMA CORPdex312.htm

Exhibit 23.2

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT

We consent to the incorporation by reference in the Registration Statements of Cell Therapeutics, Inc. on Form S-3 (File No. 333-108926, 333-134126, 333-149980, 333-149981, 333-152171, 333-157376, 333-160969, 333-163479, and 333-161442) and Form S-8 (Nos. 333-152168, 333-158260, 333-162955 and 333-170044) of our report, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, dated February 16, 2011, with respect to our audit of the consolidated financial statements of Cell Therapeutics, Inc. as of December 31, 2010 and for the year then ended, and our report dated February 16, 2011 with respect to our audit of the effectiveness of internal control over financial reporting of Cell Therapeutics, Inc. as of December 31, 2010, which reports are included in this Annual Report on Form 10-K of Cell Therapeutics, Inc. for the year ended December 31, 2010.

/s/ Marcum LLP

San Francisco, CA

February 16, 2011

Stock widget

Investing forum

CTI BIOPHARMA CORP Reports